Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (DE:SRT)
XETRA:SRT
SRT Stock Chart & Stats
€194.40
€1.00(0.53%)
At close: 4:00 PM EST
€194.40
€1.00(0.53%)
Day’s Range― - ―
52-Week Range€131.40 - €208.00
Previous CloseN/A
Volume213.00
Average Volume (3M)5.04K
Market Cap
€14.61B
Enterprise Value€20.41B
Total Cash (Recent Filing)€541.40M
Total Debt (Recent Filing)€4.45B
Price to Earnings (P/E)84.7
Beta1.39
Next Earnings
Apr 23, 2026EPS Estimate
1.31Next Dividend Ex-DateN/A
Dividend Yield0.39%
Share Statistics
EPS (TTM)1.26
Shares Outstanding37,440,000
10 Day Avg. Volume4,524
30 Day Avg. Volume5,035
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Long-term PartnershipsRecurring consumables and entrenched partnerships create predictable, annuity-like revenue. This reduces revenue cyclicality, supports steady aftermarket margins, and raises customer switching costs, providing durable topline visibility and recurring cash flow potential over the next 2–6 months and beyond.
2025 Revenue Rebound And Improved EBIT MarginA strong revenue recovery combined with meaningful operating margin expansion signals operational leverage and improving demand for core bioprocess products. Sustained higher EBIT margins enhance internal funding capacity for R&D and capex, supporting long-term competitiveness and product development.
Large Asset Base With Improving Leverage TrendA sizable asset base underpins capacity to serve large biopharma customers and supports product & service scale. The reduction in leverage from 2023 shows de-risking; ongoing balance-sheet repair increases financial flexibility for strategic investments and reduces refinancing risk over the medium term.
Bears Say
Elevated Leverage Remains MaterialDespite improvement, leverage remains elevated for a medical-instruments business and constrains flexibility. High debt increases interest and refinancing risk, limiting capacity for acquisitions or shareholder returns if operating performance weakens or macro rates rise, posing a structural headwind.
Weakened Cash Generation And Lower Free Cash FlowMaterial declines in operating cash and FCF reduce the company's ability to self-fund growth, pay down debt, or increase returns. Persistent weaker cash conversion suggests working-capital drag or higher reinvestment needs, raising the risk profile and limiting strategic optionality over the medium term.
Compressed Net Margin And Earnings VolatilityLarge gap between improved EBIT and weak net margin points to significant below‑the‑line charges, financing costs or tax impacts. This undermines sustainable profitability and cash conversion, making earnings less predictable and reducing the durability of free cash flows for creditors and investors.
Sartorius News
SRT FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was €131.40 and its highest was €208.00 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €14.61B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Apr 23, 2026 which is in 59 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Feb 03, 2026. The company reported €1.265 earnings per share for the quarter, missing the consensus estimate of €1.312 by -€0.047.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Overvalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.73 which represents an annual dividend yield of 0.39%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.31.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.265 in its last earnings report, missing expectations of €1.312. Following the earnings report the stock price went up 6.009%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in DE:SRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.06%
12-Months-Change
Fundamentals
Return on Equity
5.01%
Trailing 12-Months
Asset Growth
0.85%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
Technical Analysis
Carl Zeiss Meditec
―
Fresenius Medical Care AG & Co. KGaA
―
Fresenius SE & Co. KGaA
―
Merck KGaA
―
Siemens Healthineers AG
―
Options Prices
Currently, No data available
---